Clinical Trial Update: Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor [Phase 2]

View source ↗

Summary

Phase 2 trial update for regorafenib in patients with metastatic or unresectable gastrointestinal stromal tumor (GIST) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Suzanne George, MD | Conditions: Gastrointestinal Stromal Tumor | Phase 2 | Status: COMPLETED | Results posted: 2014-02-24